kabutan

BrightPath Biotherapeutics, Continue Net Income Turns to Loss

Fri May 9, 2025 3:30 pm JST Earnings

4594 BrightPath Biotherapeutics Co., Ltd. 【J-GAAP】

Earnings Report

BrightPath Biotherapeutics Co., Ltd. <4594> [TSE Growth] announced its financial results after the market closed on May 9th (15:30). The net loss (non-consolidated) for the fiscal year ending March 2025 was loss of 1.15 billion yen, a reduction in the deficit compared to loss of 1.15 billion yen in the previous term. For the fiscal year ending March 2026, the net loss is nearly flat with a slight increase of loss of 1.16 billion yen. This will mark the twelfth consecutive term of losses.

In the most recent three-month period, from January to March (4Q), the net loss expanded to loss of 0.33 billion yen (compared to a loss of 0.21 billion yen in the same period last year).

Kabutan News

Actual Results

Historical Performance
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2023 5 -1,467 -1,473 -1,485 -24.9 0 May 12, 2023 J-GAAP
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
YoY － -0.4% +0.9% +1.5% +22.5%

Full Year Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2025 Guidance 1 -1,114 -1,106 -1,109 -12.4 0 Mar 24, 2025 J-GAAP
Mar, 2025 Results 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
Revision Rate 0.0% -4.1% -3.7% -3.8% -13.8%

Current Period Guidance

H1 Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2024 0 -542 -537 -538 -7.1 0 Nov 8, 2024 J-GAAP
Apr - Sep, 2025 Guidance ー ー ー ー － 0 May 9, 2025 J-GAAP
YoY － － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 0 -1,155 -1,158 -1,168 -18.2 0 May 10, 2024 J-GAAP
Mar, 2025 1 -1,160 -1,147 -1,151 -14.1 0 May 9, 2025 J-GAAP
Mar, 2026 Guidance 0 -1,182 -1,164 -1,166 -10.5 0 May 9, 2025 J-GAAP
YoY － -1.9% -1.5% -1.3% +25.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jan - Mar, 2024 0 -208 -211 -215 -3.4 -Inf May 10, 2024 J-GAAP
Apr - Jun, 2024 0 -326 -329 -330 -4.7 -Inf Aug 9, 2024 J-GAAP
Jul - Sep, 2024 0 -216 -208 -208 -2.8 -Inf Nov 8, 2024 J-GAAP
Oct - Dec, 2024 0 -273 -275 -277 -3.5 -Inf Feb 14, 2025 J-GAAP
Jan - Mar, 2025 1 -345 -335 -336 -4.1 -34,500.0 May 9, 2025 J-GAAP
YoY － -65.9% -58.8% -56.3% -23.0%

Related Articles